TY - JOUR T1 - Potassium hydroxide 5% for the treatment of molluscum contagiosum JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 118 LP - 120 DO - 10.1136/dtb.2014.10.0285 VL - 52 IS - 10 A2 - , Y1 - 2014/10/01 UR - http://dtb.bmj.com/content/52/10/118.abstract N2 - Molluscum contagiosum is a common reason for consultation in primary care. The condition is normally benign and self-limiting1 and the standard advice is to wait for the lesions to resolve spontaneously.2 Recently, potassium hydroxide 5% (MolluDab—Alliance Pharmaceuticals Limited) has been marketed in the UK for the treatment of the condition.3 It is sold as a medical device rather than a licensed medicinal product. Here we consider the evidence for potassium hydroxide 5% in the management of molluscum contagiosum. ER -